JAK2 and acute lymphoblastic leukemia: While the type II JAK2i CHZ868 did effectively kill CRLF2/JAK2 mutant B-ALL cells without inducing JAK2Y1007/1008 hyperphosphorylation, this agent remained effective even in cells in which the putative molecular target (JAK2) had been genetically depleted.